The UK is squandering the vast resource of NHS patient data because too many obstacles are being placed in front of researchers trying to tap into it – holding back medical advances.
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.
Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.
Anglo-US contract development and manufacturing organisation (CDMO) Avid Bioservices has agreed a deal to be acquired by private equity firms GHO Capital Partners and Ampersand Capital Part
Alligator Bioscience has reported updated results with its CD40 agonist mitazalimab as a first-line treatment for advanced pancreatic cancer, a disease with few treatment options.<
It has been around a year since Beam Therapeutics slashed its headcount and R&D programmes to focus mainly on a sickle cell disease candidate – and the biotech has now revealed the firs